Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18242359 | 0.83 | HDAC6 (0.45) | ALDH1A1KCNN4HDAC6HDAC3HDAC1 | |
| SCHEMBL13403327 | 0.82 | PTGS1 (0.42) | ALDH1A1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL10398190 | 0.81 | KCNN4 (0.40) | ALDH1A1KCNN4PTGS1PTGS2HDAC6 | |
| SCHEMBL29727285 | 0.81 | KCNN4 (0.43) | ALDH1A1KCNN4PTGS1PTGS2HDAC6 | |
| SCHEMBL27438523 | 0.81 | KCNN4 (0.40) | ALDH1A1KCNN4HDAC6HDAC3HDAC1 | |
| SCHEMBL30069199 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KCNN4HDAC6HDAC3HDAC1 | |
| SCHEMBL2793444 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KCNN4HDAC6HDAC3HDAC1 | |
| SCHEMBL1507033 | 0.81 | KCNN4 (0.43) | ALDH1A1KCNN4PTGS1PTGS2HDAC6 | |
| SCHEMBL14398864 | 0.81 | KCNN4 (0.43) | ALDH1A1KCNN4PTGS1PTGS2HDAC6 | |
| SCHEMBL798016 | 0.80 | CA3 (0.42) | ALDH1A1PTGS1PTGS2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 703 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050053843-A1 | Non-aqueous solvent secondary battery | SANYO ELECTRIC CO., LTD. (JP) | 2005-03-10 | — | — | US | claimed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024106914-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | VORONOI INC. (KR) | 2024-05-23 | — | — | WO | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2007006546-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-01-18 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20050053843-A1 | Non-aqueous solvent secondary battery | SANYO ELECTRIC CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | ALDH1A1 363/4885KCNN4 3158/4885PTGS1 609/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | ALDH1A1 262/4885KCNN4 3249/4885PTGS1 546/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | ALDH1A1 1867/4885KCNN4 4520/4885PTGS1 1264/4885 |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | ALDH1A1 3666/4885KCNN4 4161/4885PTGS1 1594/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | ALDH1A1 3639/4885KCNN4 3939/4885PTGS1 1320/4885 |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | ALDH1A1 814/4885KCNN4 679/4885PTGS1 623/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | ALDH1A1 3939/4885KCNN4 136/4885PTGS1 1276/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | ALDH1A1 2654/4885KCNN4 4754/4885PTGS1 864/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | ALDH1A1 4225/4885KCNN4 3588/4885PTGS1 769/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | ALDH1A1 919/4885KCNN4 2061/4885PTGS1 932/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4709/4885KCNN4 4692/4885PTGS1 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.